Analyzing Teva- Pharmaceutical Industries Ltd. ADR (TEVA)’s Gross, Operating, Pretax, and Net Margins

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $13.50, up 2.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TEVA shares have gain 4.73% over the last week, with a monthly amount glided 11.57%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 26, February 2024, Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China. In a post published today on Yahoo Finance, Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders – chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

From an analyst’s perspective:

Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on February 12, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $19 from $12. Previously, Jefferies upgraded its rating to Buy on January 23, 2024, and elevated its price target to $14. On January 03, 2024, upgrade upgraded it’s rating to Neutral and revised its price target to $12 on the stock. HSBC Securities started tracking the stock assigning a Buy rating and suggested a price target of $13 on December 18, 2023. UBS upgraded its rating to a Buy and raised its price target to $13 on November 27, 2023. UBS upgraded its rating to Neutral for this stock on July 06, 2023, and upped its price target to $8. In a note dated May 25, 2023, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $10 on this stock.

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $7.09 and $13.53 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $13.50 at the most recent close of the market. An investor can expect a potential drop of -3.7% based on the average TEVA price forecast.

Analyzing the TEVA fundamentals

Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 15.84B for the trailing twelve months, which represents a growth of 13.52%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.08 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.68.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.23 points at the first support level, and at 12.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.67, and for the 2nd resistance point, it is at 13.83.

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] reported earnings per share of $1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.77/share, meaning a difference of $0.23 and a surprise factor of 29.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.6 per share as compared to estimates of $0.61 per share, a difference of -$0.01 representing a surprise of -1.60%.

Ratios To Look Out For

For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 1.02. As well, the Quick Ratio is 0.69, while the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 0.96, the price to book ratio is 2.02.

Transactions by insiders

Recent insider trading involved Daniell Richard, Exec. VP, European Commercial, that happened on Feb 28 when 20599.0 shares were sold. Executive VP Global Operations, Drape Eric completed a deal on Feb 28 to sell 9815.0 shares. Meanwhile, See “Remarks” Conway Vikki L sold 1366.0 shares on Feb 28.

Related Posts